Evidence map›Paper›PMID 29667234›Full record

ArticleBritish journal of clinical pharmacology2018

Can H

Susan J Allen, Paul L Chazot, C Jane Dixon

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Can HBritish journal of clinical pharmacology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Susan J AllenPharmacy Practice, Leicester School of Pharmacy, De Montfort University, Leicester, UK.ORCID 0000-0003-0192-3838
Paul L ChazotPharmacology, Department of Biosciences, Durham University, Durham, UK.
C Jane DixonPharmacology, Leicester School of Pharmacy, De Montfort University, Leicester, UK.
De Montfort University · GBDurham University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The anaphylactoid reaction described follows cessation of ranitidine in a 19-year-old female with the disease cluster: mast cell activation syndrome, hypermobile Ehlers-Danlos syndrome and postural tachycardia syndrome. Anaphylaxis can give wide-ranging symptoms from rhinorrhoea and urticaria to tachycardia and system-wide, life-threatening, anaphylactic shock. Individuals with a disorder of mast cell activation can experience many such symptoms. H

Indexed as

Withholding TreatmentAdultAnaphylaxisChlorpheniramineEpinephrineFemaleHistamineHistamine H1 AntagonistsHistamine H2 AntagonistsHumansRanitidineReceptors, Histamine H2Treatment OutcomeUp-RegulationYoung AdultChlorpheniramineEpinephrineHistamineHistamine H1 AntagonistsHistamine H2 AntagonistsRanitidineReceptors, Histamine H2anaphylaxishistaminemast cell activationranitidineupregulation

Identifiers

PMID29667234
PMCPMC6005605
OpenAlexW2794739863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.